{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T21:40:32Z","timestamp":1790718032616,"version":"4.1.0"},"reference-count":32,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T00:00:00Z","timestamp":1768867200000},"content-version":"vor","delay-in-days":19,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Fundamemntal Clinical Pharma"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Chronic inflammation is involved in various mechanisms of memory impairment (MI). Although Janus kinase inhibitors (JAKi), which inhibit cytokine\u2010induced JAK\u2013STAT pathway, could theoretically protect against MI, we faced an unexpected case of MI in a non\u2010elderly patient treated with JAKi.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Our study aims to investigate the association between JAKi and MI.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We searched VigiBase, the global pharmacovigilance database, for MI cases reported with JAKi from January 2011 to December 2023 and reviewed the literature for additional cases. The potential association was further explored through disproportionality analyses by calculating Reporting Odds Ratios (ROR), with statistical significance defined as a ROR and its 95% confidence interval exceeding 1.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 3788 MI cases associated with JAKi were included, 36.3% of which were serious. Over half involved non\u2010elderly patients, and co\u2010reported confounding drugs were rare. According to disproportionality analyses, MI was reported nearly three times more frequently with JAKi than with all other drugs (ROR 2.92; 95% CI: 2.83\u20133.01). To illustrate, a 54\u2010year\u2010old woman with rheumatoid arthritis treated with tofacitinib for 6\u2009months experienced MI with word\u2010finding difficulties (e.g., reduced categorical fluency: 25 animals named in 2\u2009min; norm 30\u201347) and short\u2010term memory loss, fully resolved 6\u2009weeks post\u2010discontinuation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our data support the positive association between MI and JAKi, potentially mediated through hippocampal JAK\/STAT pathway inhibition, impairing cholinergic neurotransmission and synaptic plasticity. While further investigations are warranted to confirm or refute this pharmacovigilance signal, clinicians should remain vigilant given this potentially serious adverse effect.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/fcp.70072","type":"journal-article","created":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T04:30:02Z","timestamp":1768969802000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["JAK Inhibitors and Memory Impairment: Disproportionality Analyses in the WHO Global Pharmacovigilance Database, VigiBase"],"prefix":"10.1111","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-0243-8475","authenticated-orcid":false,"given":"Marilou","family":"Dubo\u00eblle","sequence":"first","affiliation":[{"name":"Pharmacovigilance Regional Centre, Department of Medical Pharmacology and Toxicology CHU Montpellier  Montpellier France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriano","family":"Lercara","sequence":"additional","affiliation":[{"name":"IRMB, University of Montpellier, INSERM, Clinical Immunology and Osteoarticular Diseases Therapeutic Unit, Lapeyronie University Hospital CHU Montpellier  Montpellier France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yves\u2010Marie","family":"Pers","sequence":"additional","affiliation":[{"name":"IRMB, University of Montpellier, INSERM, Clinical Immunology and Osteoarticular Diseases Therapeutic Unit, Lapeyronie University Hospital CHU Montpellier  Montpellier France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9line","family":"Michel","sequence":"additional","affiliation":[{"name":"Medical Centre  Villeneuve\u2010de\u2010la\u2010Raho France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Lepelley","sequence":"additional","affiliation":[{"name":"Pharmacovigilance Regional Centre CHU Grenoble\u2010Alpes  Grenoble France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie\u2010Blanche","family":"Valnet\u2010Rabier","sequence":"additional","affiliation":[{"name":"Pharmacovigilance Regional Centre, Department of Medical Pharmacology and Toxicology CHU Besan\u00e7on  Besan\u00e7on France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0100-4073","authenticated-orcid":false,"given":"Jean\u2010Luc","family":"Faillie","sequence":"additional","affiliation":[{"name":"Pharmacovigilance Regional Centre, Department of Medical Pharmacology and Toxicology, CHU Montpellier, Desbrest Institute of Epidemiology and Public Health, Inserm Univ Montpellier  Montpellier France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginie","family":"Bres","sequence":"additional","affiliation":[{"name":"Pharmacovigilance Regional Centre, Department of Medical Pharmacology and Toxicology CHU Montpellier  Montpellier France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascale","family":"Palassin","sequence":"additional","affiliation":[{"name":"Pharmacovigilance Regional Centre, Department of Medical Pharmacology and Toxicology CHU Montpellier  Montpellier France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,1,20]]},"reference":[{"key":"e_1_2_14_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2022.09.023"},{"key":"e_1_2_14_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2020.106210"},{"key":"e_1_2_14_4_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1496401"},{"key":"e_1_2_14_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0955\u20100674(97)80067\u20101"},{"key":"e_1_2_14_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2011.11.024"},{"key":"e_1_2_14_7_1","doi-asserted-by":"publisher","DOI":"10.4161\/jkst.22925"},{"key":"e_1_2_14_8_1","doi-asserted-by":"publisher","DOI":"10.1177\/09727531211070532"},{"key":"e_1_2_14_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2010.06.012"},{"key":"e_1_2_14_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067\u2010020\u201005372\u20101"},{"key":"e_1_2_14_11_1","doi-asserted-by":"publisher","DOI":"10.15252\/embr.201847202"},{"key":"e_1_2_14_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2016.09.014"},{"key":"e_1_2_14_13_1","doi-asserted-by":"publisher","DOI":"10.1517\/14728220903213426"},{"key":"e_1_2_14_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/npp.2013.39"},{"key":"e_1_2_14_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/mp.2008.105"},{"key":"e_1_2_14_16_1","doi-asserted-by":"publisher","DOI":"10.3390\/ph18030394"},{"key":"e_1_2_14_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41392\u2010021\u201000791\u20101"},{"key":"e_1_2_14_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598\u2010022\u201010777\u2010w"},{"key":"e_1_2_14_19_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2109927"},{"key":"e_1_2_14_20_1","unstructured":"\u201cEMA Recommends Measures to Minimise Risk of Serious Side Effects With Janus Kinase Inhibitors for Chronic Inflammatory Disorders|European Medicines Agency (EMA) \u201d October 28 2022 retrieved January 20 2025 https:\/\/www.ema.europa.eu\/en\/news\/ema\u2010recommends\u2010measures\u2010minimise\u2010risk\u2010serious\u2010side\u2010effects\u2010janus\u2010kinase\u2010inhibitors\u2010chronic\u2010inflammatory\u2010disorders."},{"key":"e_1_2_14_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264\u2010025\u201001535\u20108"},{"key":"e_1_2_14_22_1","doi-asserted-by":"publisher","DOI":"10.1177\/009286150804200501"},{"key":"e_1_2_14_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.668"},{"key":"e_1_2_14_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264\u2010024\u201001423\u20107"},{"key":"e_1_2_14_25_1","unstructured":"\u201cFDA Requires Warnings About Increased Risk of Serious Heart\u2010Related Events Cancer Blood Clots and Death for JAK Inhibitors That Treat Certain Chronic Inflammatory Conditions \u201d retrieved February 5 2025 https:\/\/www.fda.gov\/media\/151936\/download?attachment."},{"key":"e_1_2_14_26_1","doi-asserted-by":"publisher","DOI":"10.2165\/00002018\u2010200730100\u201000007"},{"key":"e_1_2_14_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.30155"},{"key":"e_1_2_14_28_1","unstructured":"\u201cXeljanz Product Informations \u201d retrieved January 31 2025 https:\/\/www.ema.europa.eu\/en\/documents\/product\u2010information\/xeljanz\u2010epar\u2010product\u2010information_en.pdf."},{"key":"e_1_2_14_29_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067\u2010018\u20103990\u20109"},{"key":"e_1_2_14_30_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.CON.0000466656.59413.29"},{"key":"e_1_2_14_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.therap.2019.01.006"},{"key":"e_1_2_14_32_1","unstructured":"\u201cPractical Aspects of Signal Detection in Pharmacovigilance: Report of CIOMS Working Group VIII \u201d CIOMS 2010."},{"key":"e_1_2_14_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2021.01.015"}],"container-title":["Fundamental &amp; Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/fcp.70072","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/fcp.70072","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/fcp.70072","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T12:46:32Z","timestamp":1773060392000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/fcp.70072"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1111\/fcp.70072"],"URL":"https:\/\/doi.org\/10.1111\/fcp.70072","archive":["Portico"],"relation":{},"ISSN":["0767-3981","1472-8206"],"issn-type":[{"value":"0767-3981","type":"print"},{"value":"1472-8206","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"2025-08-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-06","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-20","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70072"}}